Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use LYBALVI® safely and effectively. See full prescribing information for LYBALVI®. LYBALVI® (olanzapine and samidorphan) tablets, for oral useInitial U.S. Approval: 2021
Medication labelWhy this: Advisory · dailymed-prescription
LYBALVI is indicated for the treatment of: Schizophrenia in adults Bipolar I disorder in adults Acute treatment of manic or mixed episodes as monotherapy and as adjunct to lithium or valproate Maintenance monotherapy treatment
- generic_name
- olanzapine and samidorphan l-malate
- product_names
- olanzapine and samidorphan L-malate
- ndc
- 65757-651, 65757-651-40, 65757-651-41, 65757-651-42, 65757-651-44, 65757-652, 65757-652-40, 65757-652-41, 65757-652-42, 65757-652-44, 65757-653, 65757-653-40, 65757-653-41, 65757-653-42, 65757-653-44, 65757-654, 65757-654-40, 65757-654-41, 65757-654-42, 65757-654-44
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en